drugset / Trial / NCT00274027

Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)

NCT00274027

Phase 3 Completed 19 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

To explore the mechanisms of dyspnea relief during exercise in patients with COPD following treatment with tiotropium bromide (Spiriva)

Timeline

Start
2001-01
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 18 ug Inhaled